PIK3CA station impact on survival in breast cancer patients and in ERalfa, PR and ERBB2-based subgroups

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F12%3A33140500" target="_blank" >RIV/61989592:15110/12:33140500 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1186/bcr3113" target="_blank" >http://dx.doi.org/10.1186/bcr3113</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/bcr3113" target="_blank" >10.1186/bcr3113</a>

Result language

angličtina

Original language name

PIK3CA station impact on survival in breast cancer patients and in ERalfa, PR and ERBB2-based subgroups

Original language description

Introduction: PIK3CA is the oncogene showing the highest frequency of gain-of-function mutations in breast cancer, but the prognostic value of PIK3CA mutation status is controversial. Methods: We investigated the prognostic significance of PIK3CA mutation status in a series of 452 patients with unilateral invasive primary breast cancer and known long-term outcome (median follow-up 10 years). Results: PIK3CA mutations were identified in 151 tumors (33.4%). The frequency of PIK3CA mutations differed markedly according to hormone receptor (estrogen receptor alpha [ER alpha] and progesterone receptor [PR]) and ERBB2 status, ranging from 12.5% in the triple-negative subgroup (ER-/PR-/ERBB2-) to 41.1% in the HR+/ERBB2-subgroup. PIK3CA mutation was associatedwith significantly longer metastasis-free survival in the overall population (P = 0.0056), and especially in the PR-positive and ERBB2-positive subgroups. In Cox multivariate regression analysis, the prognostic significance of PIK3CA mut

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/ED0030%2F01%2F01" target="_blank" >ED0030/01/01: Biomedicine for regional development and human resources</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

BREAST CANCER RESEARCH

ISSN

1465-542X

e-ISSN

—

Volume of the periodical

14

Issue of the periodical within the volume

1

Country of publishing house

GB - UNITED KINGDOM

Number of pages

9

Pages from-to

1-9

UT code for WoS article

000307444100037

EID of the result in the Scopus database

—